# Preventing Surgical Site Infections

Deverick J. Anderson, MD, MPH Associate Professor of Medicine





#### Disclosures

- Research funding from the AHRQ, NIH/NIAID, and CDC
- Royalties from UpToDate, Online





#### Outline

- Impact of SSI
- Surveillance for SSIs
- Strategies for Prevention
  - Compendium recommendations
  - Special strategies
- Implementation
- Rates and reporting





### Impact of SSI

- SSIs are the most common and most costly HAI
- An estimated 16 million operations were performed in acute care hospitals in 2010
- Prevalence
  - 2-5% of surgical patients develop an SSI
  - ~160,000-300,000 SSIs per year in US
  - SSI is now the most common and costly HAI

#### Impact

- Each SSI results in 7-11 additional hospital days
- Patients with SSI have a 2-11 times higher risk of death
- 77% of deaths among patients with SSI are directly due to SSI
- Cost (2007 dollars): \$3.5 to \$10 billion annually





#### Surveillance

- Direct vs. indirect methods
  - Indirect method reliable (sensitivity, 84%-89%) and specific (specificity, 99.8%) compared with direct surveillance
- Indirect combines
  - Review of microbiology reports and patient medical records
  - Screening for readmission and/or return to the operating room
  - Other information, such as coded diagnoses, coded procedures, operative reports, or antimicrobials ordered
  - Surgeon and/or patient surveys





### Surveillance - Electronic Data Helps

- Strategy 1 antibiotics and readmissions
  - Improve the sensitivity and reduce effort
- Strategy 2 diagnosis codes
  - Medicare claims data can be used to enhance traditional surveillance methods for SSI and to identify hospitals with unusually high or low rates of SSI





### Surveillance - Post-Discharge

Important for internal review

Not useful for hospital comparisons





### Rates and Reporting

- Rate
  - Number of infections/100 procedures
- SIR Standardized Infection Ratio
  - Number of observed infections/number of expected infections
    - >1 is bad
- Methods for risk adjustment exist, but are not very good





### Example

- SSI following colon=10
  - Number of procedures=250
- NHSN says rate of colon SSI=2.0
  - So expected number of SSIs for 250 procedures would be 5 (5/250=2 SSI/100 procedures)
- SIR = 10/5 = 2







PURPOSE



Previously published guidelines are available that provide com-

prehensive recommendations for detecting and preventing

healthcare-associated infections (HAIs). The intent of this doc-

ument is to highlight practical recommendations in a concise

format designed to assist acute care hospitals in implementing

ument is to highlight practical recommendations in a concise

healthcare-associated infections (HAIs). The intent of this doc-

prehensive recommendations for detecting and preventing

Previously published guidelines are available that provide com-



C. Each SSI is associated with approximately 7-11 addipatients,12

tional postoperative hospital-days. 25,713,14

D. Patients with an SSI have a 2-11-times higher risk of

tional postoperative hospital-days. 3,9,13,14 D. Patients with an SSI have a 2-11-times higher risk of

C. Each SSI is associated with approximately 7-11 addi-

patients.12

B. SSIs account for 20% of all HAIs in hospitalized

ventable by using evidence-based guidelines. 10,11

Lisa L. Maragakis, MD, MPH;10 Keith S. Kaye, MD, MPH11

Deverick J. Anderson, MD, MPH;1 Kelly Podgorny, DNP, MS, RN;2 Sandra I. Berríos-Torres, MD;3 Dale W. Bratzler, DO, MPH; E. Patchen Dellinger, MD; Linda Greene, RN, MPS, CIC; Ann-Christine Nyquist, MD, MSPH; Lisa Saiman, MD, MPH; Deborah S. Yokoe, MD, MPH;

#### Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update

#### SHEA/IDSA PRACTICE RECOMMENDATION

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY JUNE 2014, VOL. 35, NO. 6

#### Most Recent Update

- Compendium documents originally published in 2008
- Reconvened and diversified writing group to update (inclusion of surgeons!)
- 6 sections
  - Rationale
  - Strategies
  - Performance measures Implementation
- Detection
- Recommendations





#### What's New?

- Modification of grading of evidence
- Expansion of recommendations
  - 15 Basic Practices
  - 5 Special Approaches
  - 4 Don't Dos
  - 4 Unresolved Issues
- Addition of the section on implementation





#### Other Recent Guidelines

• WHO - 2016

• ACS - 2016

Minor differences





#### **Basic Practices - SCIP**

- Dose
- Timing
- Discontinuation
- No shaving
- Post-op glucose control
  - 180 mg/dL
  - Cardiac and non-cardiac
  - 18-24 hours after end of anesthesia
- Normothermia






### Post-op Glycemic Control

- Surgical Care and Outcomes Assessment Program in Washington State
  - 11,633 patients (57% colorectal)
- Notes
  - 25% had glucose>180
  - Hyperglycemia = 2-fold increase in SSI risk
    - Adjusted





### Post-op Glycemic Control







#### How?

- RCT of basal-bolus insulin vs. SS insulin
  - 211 general surgery patients with diabetes
- Results
  - 3.4-fold decrease in composite outcome
    - SSI, pneumonia, BSI, resp/renal failure
  - Average post-op glucose 145 v. 172 (p<0.01)
  - No statistically significant difference in patients with BG<40, but close (4 v. 0, p=0.06)






#### Basic Practices - Build on SCIP

- Weight-based dosing
- Redosing of prophylactic antibiotics for prolonged procedures
- Bowel prep





### Prophylaxis: Ideal Scenario




### Obesity and Surgical Duration

- Both significantly impact antibiotic levels in tissue
- Obesity is a risk factor for SSI
- Prolonged surgical duration is risk factor for SSI





# Prophylaxis: Obesity




### Impact of Increasing Dose

- Trial comparing 1g cefazolin v. 2g cefazolin among obese patients undergoing bariatric surgery
- Baseline rates of infection
  - 16.5/100 in obese
  - 2.5/100 in non-obese (undergoing other clean-contaminated surgery)
- Tissue and serum concentrations were lower in patients who received 1g (p<0.0001)</li>
- Rate decreased to 5.6/100 procedures in obese patients





### Prophylaxis: Long Procedure







### Re-Dosing: Data Show it Works

- Review of published literature
- Analysis of 801 patients undergoing cleancontaminated operations:
  - 1g cefazolin
  - 1g cefazolin + 1g 3 hours later
- If procedure > 3 hours, then rate of SSI reduced from 6.1 to 1.3





### MBP (no PO abx) and SSI

tudy name	Events / Total		Statistics for each study					Odds ratio and 95% CI				
	MBP	NO MBP	Odds ratio	Lower limit	Upper limit	p-Value						Relativ weigh
Prownson 1992	21 / 86	10 / 93	2,682	1,181	6,089	0,018	- 1	- 1	1-	<b>—</b> I	1	7.
Burke 1994	7 / 82	7 / 87	1,067	0,357	3,185	0,908	- 1	- 1 -	$\rightarrow$	-		5,
Santos 1994	24/72	13 / 77	2,462	1,138	5,326	0,022	- 1		<b></b>	<b>—</b> I		7,
(ale1997	8/62	1/20	2,815	0,330	24,010	0,344		-	-			1,
fiettinen 2000	13 / 138	10 / 129	1,238	0,523	2,930	0,628	- 1		<del></del>	.		6,
illmann 2001	3/30	3/30	1,000	0,185	5,403	1,000	- 1	I —	$\rightarrow$	_		2,
oung-Tabusso 2002	3/24	0/23	7,651	0,373	156,840	0,187	- 1	- 1	-		→	0
mora 2003	19 / 187	17 / 193	1,171	0,589	2,329	0,653			<del></del>			8
a-Si-Oen 2005	16 / 125	13 / 125	1,265	0,581	2,753	0,554	- 1		<b></b> -	.		7.
am 2005	18 / 164	12 / 165	1,572	0,732	3,377	0,246	- 1		+-	-		7.
Sucher 2005	17 / 78	6/75	3,205	1,188	8,646	0,021	- 1		I—			5,
ena 2007	19 / 48	11 / 49	2,263	0,933	5,489	0,071	- 1		<b>⊢</b>	_		6.
ung 2007	82 / 686	83 / 657	0,939	0,678	1,301	0,704	- 1		+			14,
ontant 2007	135 / 670	165 / 684	0,794	0.614	1,027	0,079	- 1		-			15,
			1,403	1,054	1,869	0,020	- 1		-			, ,
			.,	.,	1,000	-,	0,01	0,1	1	10	100	
							0,01	0,1	1	10	100	
								Favors MBP		Favors NO MBP		





#### MBP and Harm? Anastamotic Leak

Study name	Events	/ Total	Statist	ics for ea	ch study		Odds ratio and 95% CI					
	MBP	NO MBP	Odds ratio	Lower limit	Upper limit						Relative weight	
Brownson 1992	8/67	1 / 67	8,949	1,087	73,690	1	1	<u> </u>	-	1	2,17	
Burke 1994	3/82	4/87	0,788	0,171	3,633		- 1	_	-e: I		4,12	
Santos 1994	7/72	4/77	1,965	0,550	7,020			133			5,94	
Kale1998	1/62	0/20	1,000	0,039	25,519		34114	_		8 3	0,92	
Miettinen 2000	5 / 138	3 / 129	1,579	0,370	6,744						4,57	
Fillmann 2001	2/30	1/30	2,071	0,178	24,148		-		_		1,60	
Young-Tabusso 20	0023/24	0/23	7,651	0,373	156,840						1,06	
Zmora 2003	7 / 187	4 / 193	1,838	0,529	6,384						6,21	
Fa-Si-Oen 2005	7 / 125	6 / 125	1,177	0,384	3,605				- 0		7,68	
Ram 2005	1 / 164	2 / 165	0,500	0,045	5,568		F1 - 1			- 1	1,66	
Bucher 2005	5/78	1 / 75	5,068	0,578	44,446						2,04	
Pena 2007	4 / 48	2/49	2,136	0,373	12,251				-		3,16	
Jung 2007	13 / 686	17 / 657	0,727	0,350	1,509						18,06	
Contant 2007	32 / 670	37 / 684	0,877	0,540	1,425			-			40,83	
			1,124	0,824	1,532			+		4		
						0,01	0,1	1	10	100		
						Association (	Favors MB	P Fa	vors NO M	IBP		







#### Oral + IV Antibiotics?

- Reviewed 182 RCTs comparing different prophylactic regimens
  - Elective and emergency procedures included
- 13 trials met criteria to compare combined oral and intravenous antibiotic vs. IV alone





#### Oral + IV Antibiotics?

Analysis 6.1. Comparison 6 Combined oral and intravenous versus oral or intravenous alone, Outcome I Surgical wound infection: oral + iv versus iv alone.

Review: Antimicrobial prophylaxis for colorectal surgery

Compartsors 6 Combined oral and intravenous versus oral or intravenous alone

Outcome: I Surgical wound infections oral + iv versus iv alone

Rev

VS.

Study or subgroup Combined Oral % IV IV Alone Risk Ratio Walght Risk Ratio n/N M-H.Random,95% CI M-H,Random,95% CI n/N Coppa 1988 9/169 15/141 10.5 % 0.50 [ 0.23, I.11 ] Espin-Basany 2005 15/200 6/100 85% 1.25 [ 0.50, 3.12 ] 0.46 [ 0.21, 1.01 ] Ishida 2001 8/72 17/7 11.0 % Kalser 1983 2/63 7/56 35% 0.25 [ 0.06, IL17 ] 0.31 [0.12, 0.78] Khubchandani 1989 14/47

3/65 5/67 4.1% 0.62 [ 0.15, 2.48 ] com Lazorthes 1982 1/30 7/30 2.0 % 0.14 [ 0.02, 1.09 ] Lewts 2002 5/104 17/104 7.8 % 0.29 [ 0.11, 0.77 ] McArdle 1995 8/62 20/87 11.4% 0.56 [ 0.26, 1.19 ]

9.45 [ 0.53, 169.95 ] Peruzzo 1987 4/39 Reynolds 1989 9/107 26/223 12.1 % 0.72 [ 0.35, 1.49 ] Stellato 1990 3/51 2/51 2.7% 1.50 [ 0.26, 8.60 ]

Taylor 1994 0.60 [ 0.34, 1.04 ] 17/159 30/168 17.2 % Total (95% CI) 1176 1186 100.0 % 0.55 [ 0.41, 0.74 ]

Total events: 89 (Combined Oral % IV), 166 (IV Alone) Heterogeneity:  $Tau^2 = 0.05$ ;  $Chi^2 = 14.78$ , df = 12 (P = 0.25);  $I^2 = 19\%$ 

Test for overall effect; Z = 3.93 (P = 0.000084)

Favours treatment Favours control Nelson et al. Cochrane Database Syst Rev 2009; 21:CD001181

01 02 05 1 2 5 10







ent

luded

### Basic Practices - Beyond SCIP

- Oxygenation
- Skin prep
- Use of plastic wound protectors
- WHO checklist





### Oxygen and SSI: Basic Science

- O<sub>2</sub> is important for wound healing
- O<sub>2</sub> correlated with collagen deposition
- Tissue hypoxia is a risk factor for wound infection and dehiscence
- Superoxide production by leukocytes proportional to Po2
- Many antibiotics require oxygen to exert lethal effects on bacteria





### High Inspired O<sub>2</sub> Fraction

- Several studies have compared FiO<sub>2</sub> of 80% vs. 30%
- 5 RCTs
  - Mayzler (2005; Minerva Anesthesiol)
    - n=38; colorectal procedure for metastatic dz;
  - Pryor (2004; JAMA)
    - n=160; major abd surgery; SSI rate 2-fold higher in intervention group; high rates of obesity; SSI in 14d
  - Belda (2005; JAMA)
    - n=291; elective colorectal; O<sub>2</sub> for 6 hours; SSI in 14d
  - Greif (2000; NEJM)
    - n=500; elective colorectal; SSI in 15d
  - Myles (2007; Anesthesiology)
    - n=2002; non-CT surgery; SSI in 30d






# High Inspired O<sub>2</sub> Fraction

- Recent meta-analysis reviewed 5 RCTs
  - Variation in methods noted
    - 3 included nitrous oxide mixture
    - 1 provided O2 for 6 hours
    - 3 colorectal
    - Antibiotic prophylaxis not controlled for in all
- By fixed-effects method, data supports use of 80% FiO2 for prevention of SSI





# High Inspired O<sub>2</sub> Fraction







#### Harm?

- PROXI Trial
  - n=1400 patients undergoing acute or elective laparotomy
  - Randomized to 80% v. 30% FiO<sub>2</sub>
  - SSI dx in 14 days
- No difference in rates of SSI for two groups
  - Approx 20% for each group
  - Adjusted RR=0.91 (0.69 to 1.20)
- No difference in adverse outcomes between two groups





#### Harm?

PROXI Trial recently published

n-1400 nationts undergoing acute or elective

MET MULL BATTABLE TIBARKANI	AA AEIITA AE AIA	· · · · · · · · · · · · · · · · · · ·
Characteristic	80% Oxygen (n = 685)	30% Oxygen (n = 701)
Surgical procedure, No. (%) Colorectal procedures	303 (44.2)	330 (47.1)
Gynecological procedures	139 (20.3)	129 (18.4)
Small-bowel surgery	78 (11.4)	80 (11.4)
Appendectomy	61 (8.9)	63 (9.0)
Other <sup>b</sup>	104 (15.2)	99 (14.1)
Receiving adequate antibiotic prophylaxis, No. (%)	580 (84.7)	589 (84.0)
Receiving timely antibiotic prophylaxis, No. (%) <sup>e</sup>	432 (66.8)	448 (68.1)
	-	4

 No difference in adverse outcomes between two groups





80%

30%

• PROXI Tria	Adverse Event Any Wound-related	Oxygen (n = 685) 361 (52.7) 61 (8.9)	Oxygen (n = 701) 369 (52.6) 77 (11.0)	aloctivo
Charac		23 (3.4)	34 (4.9)	30% Oxygen (n = 701)
Surgical procedure, No. (%) Colorectal procedures	Postoperative nausea	79 (11.5) 136 (19.9)	83 (11.8) 135 (19.3)	330 (47.1)
Gynecological procedur Small-bowel surgery	Respiratory	63 (9.2) 57 (8.3)	57 (8.1) 67 (9.6)	129 (18.4) 80 (11.4)
Appendectomy Other <sup>b</sup>	Gastrointestinal tract Other	61 (8.9) 150 (21.9)	62 (8.8) 152 (21.7) H	63 (9.0) 99 (14.1)
Receiving adequate antibio	-Any serious adverse event	165 (24.1) 21 (3.1)	154 (22.0) H	589 (84.0) 448 (68.1)
<ul> <li>No differer</li> </ul>	Other infection	29 (4.2)	34 (4.9)	between
two groups	Respiratory Circulatory	27 (3.9) 24 (3.5)	25 (3.6)	
<b>Duke</b> Medicir	Other  Ivieynori et al. JANIA Hunt and Hopf. JAN			DUKE INFECTION CONTROL OUTREACH NETWORK

## Skin Prep

- Use alcohol-containing skin prep (when possible)
- Add a disinfectant, but choice is unclear based on published data
- More to be said on this topic later...





#### CHG Uses in Infection Control

Application	Evidence				
Skin antisepsis					
CVC site preparation	50% better than povidone-iodine (catheter colonization)				
Surgical hand scrub	86-92% reduction in flora				
Source control in ICUs	Reduction in skin flora; reduce risk of CLABSI 6-fold				
Preoperative scrub	Superior to other antiseptics in reducing skin flora at surgical site				
Impregnated devices					
Vascular catheter dressings	Reduction in catheter colonization (40-50%); decrease rate of CLABSI				
Vascular catheters	Reduction in catheter colonization (55%); in BSI (40%) in high-risk groups				





#### CHG v. PI?

- Finally, RCT comparing CHG-ETOH vs. PI-ETOH
- 1,147 women undergoing CSEC
- Rate of SSI lower with CHG/EtOH (p=0.02)
  - CHG/EtOH SSI rate=3.0
  - PI/EtOH SSI rate=4.9






#### CUC V DI2

Subgroup	Chlorhexidine– Alcohol	Iodine– Alcohol	Relative Risk (95% CI)	P Value fo Interaction			
	no. of events/	total no.	, ,				
Type of cesarean deliv	ery			0.22			
Scheduled	8/334	21/335	0.38 (0.17–0	).85)			
Unscheduled	15/238	21/240	0.72 (0.38–1	1.36)			
Obese			i 1	0.70			
Yes	18/402	30/387	0.58 (0.33–1	1.02)			
No	5/170	12/188	0.46 (0.17–1	28)			
Skin-closure type				0.12			
Staples	9/108	9/107	0.99 (0.41–2	2.40)			
Suture	14/464	33/467	0.43 (0.23–0	).79)			
Chronic medical cond	ition		1	0.59			
Yes	5/107	11/101	0.43 (0.15–1	1.19)			
No	18/465	31/474	0.59 (0.34–1	1.04)			
Diabetes				0.84			
Yes	2/55	5/65	0.47 (0.10–2	2.34)			
No	21/517	37/510	0.56 (0.33–0	).94)			
			0.2 1.0 5.0				
			Chlorhexidine-Alcohol Iodine-Alcohol Better Better				







## FDA Warning: CHG

- FDA released a Safety Communication warning about potential for rare but serious allergic reactions to CHG
- Data
  - 1969-2015: 52 cases of anaphylaxis (2 deaths)
  - Big increase since 2010
- While need to monitor for these important reactions, this issue does not change recommendations about CHG





#### Impervious Plastic Wound Protectors

- Plastic sheath that facilitates retraction
- Theoretically improves health of tissue
- GI and biliary tract procedures






#### Impervious Plastic Wound Protectors

Plasti

Theol

• GI an





Edwards et al. Ann Surg 2012; 256:53-59.







- Checklists
  - Proven method for prevention of complications
    - Change system AND individual behavior
  - CLABSI
- New checklist for surgical care
  - 19 item surgical safety checklist
    - Sign in, Time out, Sign out
  - 8 institutions throughout world
  - Prospective, quasi-experimental study of patients before (n=3733) and after (n=3955) implementation
  - Non-cardiac surgery
  - During "Time-Out," OR team had to confirm that prophylactic antibiotics have been administered ≤60 min before incision is made or that antibiotics are not indicated





Table 2. Characteristics of Participating Hosp	itals.
--	--------

Site	Location	No. of Beds	No. of Operating Rooms	Туре
Prince Hamzah Hospital	Amman, Jordan	500	13	Public, urban
St. Stephen's Hospital	New Delhi, India	733	15	Charity, urban
University of Washington Medical Center	Seattle, Washington	410	24	Public, urban
St. Francis Designated District Hospital	Ifakara, Tanzania	371	3	District, rural
Philippine General Hospital	Manila, Philippines	1800	39	Public, urban
Toronto General Hospital	Toronto, Canada	744	19	Public, urban
St. Mary's Hospital*	London, England	541	16	Public, urban
Auckland City Hospital	Auckland, New Zealand	710	31	Public, urban





Site No.	No. of F			Prophylactic Antibiotics Given Surgical-Site Appropriately Infection (N=6802)		Dea	ath	Any Complication		
	Before	After	Before	After	Before	After	Before	After	Before	After
					perce	nt				
1	524	598	4.0	2.0	98.1	96.9	1.0	0.0	11.6	7.0
2	357	351	2.0	1.7	56.9	76.9	1.1	0.3	7.8	6.3
3	497	486	5.8	4.3	83.8	87.7	0.8	1.4	13.5	9.7
4	520	545	3.1	2.6	80.0	81.8	1.0	0.6	7.5	5.5
5	370	330	20.5	3.6	29.8	96.2	1.4	0.0	21.4	5.5
6	496	476	4.0	4.0	25.4	50.6	3.6	1.7	10.1	9.7
7	525	585	9.5	5.8	42.5	91.7	2.1	1.7	12.4	8.0
8	444	584	4.1	2.4	18.2	77.6	1.4	0.3	6.1	3.6
Total	3733	3955	6.2	3.4	56.1	82.6	1.5	0.8	11.0	7.0
P value			<0.0	001	<0.	001	0.0	03	<0.	001





#### Other Interventions

- Maintain normothermia
- Surveillance
  - Use automated data
  - Feedback data to surgeons/surgical personnel
  - Provide education to surgeons and patients





#### Special Strategies - To Do or Not?

- "Duke" colorectal bundle
  - Glove change for closure?
- Screening and decolonization for S. aureus
- Antimicrobial sutures






#### The Duke Colorectal Bundle

- High adverse outcomes following colorectal procedures (>20%)
  - ACS-NSQIP data
- Created and implemented a "bundle" of evidence-based and "common sense" interventions
  - Multidisciplinary
  - Monthly review meetings
  - Items included on a "checklist"





## **Bundle Components**





Keenan et al. JAMA Surg 2014;149:1045.



#### Results

- Retrospective analysis of 559 randomly selected patients from 2008 through 2012
  - Propensity matched on multiple potential confounders (age, sex, BMI, DM, chemo, XRT, total op time, lap approach, rectal)
  - 212 patients in each group
    - No major differences in patient characteristics





#### Results

	Prebundle (n=212)	Postbundle (n=212)	p-value
Superficial-incisional SSI	41 (19.3)	12 (5.7)	<0.001
Deep-incisional SSI	3 (1.4)	0	0.25
Organ-Space SSI	11 (5.2)	6 (2.8)	0.32
Wound disruption	5 (2.4)	3 (1.4)	0.72
Postop sepsis	18 (8.5)	5 (2.4)	0.009
LOS - med (IQR)	5.5 (4-8)	5.0 (3-7)	0.05
30-d readmit	32 (15.1)	19 (9.0)	0.14





## Successes/Challenges

- Bundle considered a success
  - Increased adherence to evidence-based and systematic practices
  - Key "implementation" components:
    - Multidisciplinary
    - Monthly review, open discussion
- Limitations
  - Retrospective, quasi-experimental
  - Elective procedures only
  - Bundle component vs. all?
- Challenges
  - What components to include?
  - Scheduling
  - Prioritization
  - Must have a surgeon "champion"





## Glove/Instrument Change

- ACS/SIS recommended changing gloves and instruments for closure in colorectal surgery
- Based on expert concensus
- Frankly, not a bad idea






#### SA Screening/Decolonization

- If known to be colonized, should decolonize
  - ASHP, WHO, ACS, SHEA
- BUT
  - Should you screen??
- Controversial!





## SA Screening/Decolonization





Schweizer et al. JAMA 2015;313:2162.



## SA Screening/Decolonization

- Many factors to consider
  - Baseline rate of *S. aureus* SSI
  - Adherence to basic practices
  - Ability to follow up protocol
  - Resources to implement protocol
  - How to screen? How to decolonize?
- Currently recommended as a "Special Approach"





#### **Antimicrobial Sutures**

- Important:
  - Foreign devices increase the risk of SSI
    - Presence of sutures decreases inoculum required for SSI
      - $-10^6$  to  $10^2$
- SHEA/IDSA guidelines not recommended
- WHO and ACS guidelines recommended for clean and clean-contaminated abdominal cases
  - Meta-analysis published in 2016 that included 6 additional RCTs





#### **Antimicrobial Sutures**

	Triclosan-coated Uncoat		ted	Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	r M-H, Fixed, 95% CI	
Deliaert 2009	0	26	0	26		Not estimable	2009	9	
Rasic 2011	4	91	12	93	3.4%	0.34 [0.11, 1.02]	2011	1	
Galal 2011	17	230	33	220	9.7%	0.49 [0.28, 0.86]	2011	1	
Baracs 2011	23	188	24	197	6.8%	1.00 [0.59, 1.72]	2011	1 +	
Williams 2011	10	75	14	75	4.0%	0.71 [0.34, 1.51]	2011	1 -+	
Zhang 2011	2	51	5	50	1.5%	0.39 [0.08, 1.93]	2011	1 ———	
Seim 2012	16	160	17	163	4.9%	0.96 [0.50, 1.83]	2012	2 +	
Turtiainen 2012	31	139	30	137	8.7%	1.02 [0.65, 1.59]	2012	2 +	
Isik 2012	9	170	19	340	3.7%	0.95 [0.44, 2.05]	2012	2 —	
Thimour-Bergstrom 2013	23	184	38	190	10.8%	0.63 [0.39, 1.01]	2013	3	
Nakamura 2013	9	206	19	204	5.5%	0.47 [0.22, 1.01]	2013	3 —	
Justinger 2013	31	485	42	371	13.7%	0.56 [0.36, 0.88]	2013	3	
Diener 2014	87	587	96	598	27.4%	0.92 [0.71, 1.21]	2014	4 -	
Total (95% CI)		2592		2664	100.0%	0.76 [0.65, 0.88]		•	
Total events	262		349					200	
Heterogeneity: Chi <sup>2</sup> = 14.57	, df = 11 (P = 1	0.20);  2=	= 25%						
Test for overall effect; Z = 3.							F	0.01 0.1 1 10 100 Favours triclosan-coated Favours uncoated	





#### Unresolved

- CHG baths before surgery
- Intranasal CHG
- Antibiotic-impregnated, implantable sponges
  - Gentamicin





# One Last Thought about Interventions

- SCIP SSI measures have been largely removed
- Cynical view
  - All the gain in best practices via SCIP will gradually degrade
- So...
  - Need to remain vigilant for increases in SSI during and after transition
  - Can SCIP measures still be tracked??





## Implementation

- Based on 4 Es
  - Engage
    - Clear communication about why important
      - Ex: physician champions
  - Educate
    - The "what to do/not do"
      - Ex: Education for patients/family
  - Execute
    - Reduce barriers and improve adherence
      - Ex: QI methodology (six sigma, etc.)
  - Evaluate
    - Measurement
      - Ex: Longitudinal evaluation of outcomes and process





## Role of IP in Implementation

#### Engage

- Involve hospital leadership
- Identify physician champions
- Identify multidisciplinary teams
- Evidence-based practices
- Foster a culture of safety

#### Educate

- Patients, surgeons, leadership





## Role of IP in Implementation

#### Execute

- Quality improvement strategies
- Maximize IT
- Participate in a network/collaborative
- Order sets
- Protocols
- Act on problems once identified!!

#### Evaluate

- Surveillance





#### Take Home Points

- SSI is the most common and most costly HAI
- Many different strategies are required to reduce SSI risk to lowest extent possible
- IPs play a critical role
- Not every hospital needs to approach SSI prevention the same way
  - But all hospitals need to at least use the basic strategies





## Questions?



